$ALBPS News

Last published 5y ago

5y agoBPTS ALBPSBiophytis Reports H1 2021 Financial Results and Provides Business UpdateGlobeNewswireSARA-INT: Positive top line results of Phase 2 study demonstrate efficacy of Sarconeos (BIO101) in sarcopenia and support progress into Phase 3 COVA: DMC second interim analysis shows efficacy results in the promising zone allowing continuation of the
5y agoBPTS ALBPSBiophytis Announces DMC Second Interim Analysis Efficacy Results in the Promising Zone Allowing Continuation of Phase 2/3 COVA Study With Sarconeos (BIO101) in COVID-19GlobeNewswireThe independent DMC (Data Monitoring Committee) recommends continuation of Part 2 of the Phase 2-3 Study ("the COVA Study") without any protocol amendment The second Interim Analysis ("IA2") based on 155 hospitalized patients shows no futility, with ef
5y agoBPTS ALBPSBiophytis to Attend Key Upcoming Investor Events and Industry ConferencesGlobeNewswirePARIS and CAMBRIDGE, Mass., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associate
5y agoBPTS ALBPSBiophytis Leadership is Reinforced With New Chief Medical Officer AppointmentGlobeNewswireRob van Maanen MD, MBA, FFPM, becomes Chief Medical Officer, member of the Executive Committee PARIS and CAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnol
5y agoBPTS ALBPSBiophytis Receives Favorable Recommendation From Data Monitoring Committee (DMC) Based on Safety Analysis of Sarconeos (BIO101) to Continue Patient Recruitment in the COVA Study in COVID-19GlobeNewswireThe independent DMC (Data Monitoring Committee) of the COVA study recommends to continue patients recruitment into Part 2 of the phase 2-3 study following randomization of the first 155 patients Efficacy data from the second Interim Analysis is expecte
5y agoBPTS ALBPSBiophytis Announces the Issue of 4,950,000 New Shares in a Capital Increase Reserved for NEGMA and the Performance of the Judgments of March 16, 2021 and July 16, 2021GlobeNewswirePARIS and CAMBRIDGE, Mass., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), ("Biophytis" or the "company"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the d
5y agoBPTS ALBPSBiophytis Announces Top Line Results of SARA-INT Phase 2 Study With Sarconeos (BIO101) in SarcopeniaGlobeNewswireSarconeos (BIO101) at the highest dose (350 mg bid) showed a clinically meaningful improvement in the 400-meter walk test (400MWT), the primary endpoint of the study Sarconeos (BIO101) showed a very good safety profile at the doses of 175 mg bid and of
5y agoBPTS ALBPSJudgment Rendered on July 16, 2021 in the Proceedings Between Biophytis and Negma Group Ltd by the Execution Judge From the Paris Court of JusticeGlobeNewswirePARIS and CAMBRIDGE, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the d
5y agoBPTS ALBPSBiophytis Presents Positive Preclinical Data on Sarconeos (BIO101) in COVID-19 at ECCMID 2021GlobeNewswirePARIS and CAMBRIDGE, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), ("Biophytis" or the "company"), a clinical-stage biotechnology company focused on the development of therapeutics that are aimed
5y agoBPTS ALBPSBiophytis Reinforces Leadership Teams with Three Senior AppointmentsGlobeNewswireClaude Allary to be member of Board of Directors Benoit Canolle is appointed Chief Business Officer Jean Mariani, Chairman of Biophytis Scientific Committee to take over the Chief Medical Officer role PARIS and CAMBRIDGE, Mass., July 08, 2021 (
5y agoBPTS ALBPSBiophytis Secures the Manufacturing of Sarconeos (BIO101) for COVID-19 with a Global CDMO & Announces the Next Milestones for the COVA Phase 2-3 StudyGlobeNewswireThe Company signed contracts for the manufacturing of registration batches in view of the potential application for Emergency Use Authorization to FDA and/or Conditional Marketing Authorization to EMA The 155th patient has completed treatment in Part 2
5y agoBPTS ALBPSResults of Biophytis SARA-INT Phase 2 Trial with Sarconeos (BIO101) in Sarcopenia will be Released by August 2021GlobeNewswirePARIS and CAMBRIDGE, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), ("Biophytis" or the "company"),a clinical-stage biotechnology company focused on the development of therapeutics that are aimed
5y agoBPTS ALBPSBiophytis announces new convertible bond financing for up to €32 million with Atlas and drawing of 2 tranches under the 2020 Atlas Contract for €6 millionGlobeNewswirePARIS and Cambridge, Mass., June 19, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company focused on the development of therapeutics aimed at slowi
5y agoBPTS ALBPSBIOPHYTIS Completed Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the 2nd Interim AnalysisGlobeNewswireThis 2nd interim analysis is to be performed by the independent DMC (Data Monitoring Committee) based on safety and efficacy data The Company is to report the recommendation from the DMC based on its review of second interim analysis by end of Q2 2021,
5y agoBPTS ALBPSBIOPHYTIS - Results of the Combined General Meeting on May 10, 2021GlobeNewswirePARIS, France and CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- BIOPHYTIS SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), ("BIOPHYTIS" or the "company"), a clinical-stage biotechnology company focused on the development of therapeutics that ar
5y agoBPTS ALBPSBiophytis – Second Combined General Meeting to Take Place on May 10, 2021 without the physical presence of its shareholdersGlobeNewswirePARIS and CAMBRIDGE, Mass., April 30, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics aimed at slowing the degenerative processes associated with ag
5y agoBPTS ALBPSBiophytis Receives €980,000 DeepTech Funding from BPI France for the development of Macuneos (BIO201) in Dry AMDGlobeNewswireDeepTech funding supports advanced and highly differentiating biotech projects with significant commercial potential Biophytis plans to initiate Phase 1 clinical trial in the second half of 2021 PARIS and CAMBRIDGE, Mass., April 29, 2021 (GLOBE N
5y agoBPTS ALBPSBiophytis - Convening of Another Combined General Meeting at a Later DateGlobeNewswirePARIS and CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics aimed at slowing the degenerative processes associated with ag
5y agoBPTS ALBPSBiophytis Gives Operational Perspectives on its Sarconeos (BIO101) Ahead of its Upcoming AGM on April 26, 2021GlobeNewswirePARIS and CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associate